« Back
Home /
Protosappanin A

Protosappanin A

Item no.	TMO-TJS1779-5mg
Manufacturer	TargetMol
CASRN	102036-28-2
Amount	5mg
Category	Reagents & Chemicals Biochemicals
Type	Chemicals
Specific against	other
Smiles	Oc(cc1)cc(OCC(C2)=O)c1-c(cc1O)c2cc1O
ECLASS 10.1	32160000
ECLASS 11.0	32160000
UNSPSC	12000000
Alias	PTA
Available
Short Description	Protosappanin A has anti-oxidative/nitrative activities on brain immune and neuroinflammation through regulation of CD14/TLR4-dependent IKK/IÎºB/NF-ÎºB inflammation signal pathway; it exerts anti-neuroinflammatory effect by inhibiting JAK2-STAT3 pathway in lipopolysaccharide-induced BV2 microglia. Protosappanin A induces immunosuppression of rats heart transplantation targeting T cells in grafts via NF-kappaB pathway. Protosappanin A and protosappanin B have antimicrobial activity, they show both alone activities and resistance reversal effects of amikacin and gentamicin against MRSA. Protosappanin A shows strong effect against HIV-1 IN with an IC50 value of 12.6 uM.
Shipping	cool pack
Storage	-20°
Target names or alias	PTA
Molecular Weight	272, 25
Pathway	Immunology/Inflammation\|\|\|Neuroscience\|\|\|Chromatin/Epigenetic\|\|\|Angiogenesis\|\|\|Stem Cells\|\|\|Apoptosis\|\|\|Proteases/Proteasome\|\|\|NF-Κb\|\|\|JAK/STAT signaling\|\|\|Microbiology/Virology
Target	TNF\|\|\|ROS\|\|\|HIV Protease\|\|\|JAK\|\|\|NF-κB\|\|\|IκB/IKK\|\|\|COX\|\|\|STAT\|\|\|NO Synthase\|\|\|IL Receptor\|\|\|NADPH-oxidase\|\|\|TLR

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 5mg

available

Delivery expected until 8/30/2024